230 likes | 264 Views
Protein Therapeutics: Delivery. Devin Hudson. Delivery Methods. Intravenously Subcutaneously Suppository Intranasally Orally * Transinfection *. Liquid Filled Nanoparticles as a Drug Delivery Tool.
E N D
Protein Therapeutics: Delivery Devin Hudson
Delivery Methods • Intravenously • Subcutaneously • Suppository • Intranasally • Orally* • Transinfection*
Liquid Filled Nanoparticles as a Drug Delivery Tool. Venkatesan, N., Yoshimitsu, J., Ito, Y., Shibata, N. Takada, K. (2005) Biomaterials. 26, 7154-7163.
Barriers to Oral Bioavailability • Percent Bioavailability: BA% • Poor Membrane Permeability • Enzymatic Degradation • Past Attempts: liposomes, nanoparticles, micro-spheres, hydragels, mucoadhesives, micro-emulsions
Erythropoietin (EPO) Hormone: Produced in Kidneys Erythropoiesis 1BUY 1BUY 1BUY PDB: 1BUY
Porous Absorbents Carbon Nano Tube Carbon Nanohorn Fullerenes Other Porous Substrates: Silicon Dioxide, Charcoal, bamboo charcoal
Treatment Jejunum: large surface area Blood EPO measured via Jugular vein with ELISA
Absorption Enhancers Formulation G: labrasol
Porous Absorbents Formulation A: CNT
Protease Inhibitors casein vs lactoferrin Formulation G: Casein
Conclusion BA% = 11.5
Systemic Delivery of Secreated Protein by Grafts of Epidermal Keratinocyctes: Prospects for Keratinocyte Gene Therapy. Fenjves, E. S., Smith, J., Zaradic, S. and Lorne, B. T. (1994) Human Gene Therapy. 5, 1241-1248 Wikipedia.org
Concept Transfect with recombinant apoE-HA1 (pSV2neo) ELISA: Two Tests Graft skin Wikipedia.org
Keratinocyctes and Aythmic Mice Stable Long Term Grafts Effectively Transduced via retrovirus Secretory tissue Newborn Foreskin Immune- deficient No Rejection Response Xenografts Wikipedia Nude Mouse
Fractionation – Ficoll 400 Non-fractionated: total Small: basal compartment rich Intermediate: poorly characterized Large: terminally differentiated suprabasal cells Basal compartment keratinocyctes excrete endogenous apoE Mature Differentiated keratinocyctes do not excrete endogenous apoE Recomibant apoE expressed by any transfected keratinocytes
Long Term Success Blood Serum apoE after 28 days Previous work: Viral promoters shut off over time
Conclusion Higher Recombinant Expression in vivo Expansion in suprabasal cells in grafts Estimated that graft covering 2% of human skin could provide 6.5-8.9mg of recombinant protein per day.
Oral vs Graft Pros: Doesn’t Require On-Going Care Lower Long Term Expense Less Margin for Patient Error Less Risky than Systemic Transfection Cons: Invasive Treatment Can Not be Stopped Easily Pros: Easily Manage Dosing Quit/Start/Change Treatment Minimally Invasive Lower Short Term Expense Cons: Require On-going Care Suffer from Varied Absorption
Refrences • Skin Patch • Fenjves, E. S., Smith, J., Zaradic, S. and Lorne, B. T. (1994) Systemic Delivery of Secreated Protein by Grafts of Epidermal Keratinocyctes: Prospects for Keratinocyte Gene Therapy. Human Gene Therapy. 5, 1241-1248. • Review Paper • Leader, B., Baca, Q, J,. and Golan, D, E. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Publishing Group. 7, 21-39. • Oral • Venkatesan, N., Yoshimitsu, J., Ito, Y., Shibata, N. Takada, K. (2005) Liquid filled nanoparticles as a drug delivery tool. Biomaterials. 26, 7154-7163.